Compare Vanguard Total International Bond Index Fund ETF (BNDX) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Total International Bond Index Fund ETF vs Crispr Therapeutics AG — how do they compare? Vanguard Total International Bond Index Fund ETF trades at $47.81, while Crispr Therapeutics AG trades at $54 (market cap $5.23B). The key difference: Crispr Therapeutics AG is trading nearer its 52-week high, Vanguard Total International Bond Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| BNDX | CRSP | |
|---|---|---|
52-Week High | $49.91 | $76.78 |
52-Week Low | $47.57 | $44.34 |
Market Cap | — | $5.23B |
Sector | — | Health |
Enterprise Value | — | $3.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNDX trades at $47.82, up 0.06% on the day, amid a bearish technical signal with moving averages indicating selling pressure and oscillators neutral. Recent news highlights institutional activity, including Apella Capital reducing its stake and Archer Investment Management increasing holdings. The fund's dividend schedule shows consistent payouts, with the latest dividend of $0.12 scheduled for payment in August 2026.
The outlook for BNDX is cautious due to bearish technical indicators and mixed institutional sentiment. Risks include interest rate volatility and inflation concerns, as highlighted by recent Treasury yield movements. Opportunities lie in its role as a bond ETF providing diversified international fixed income exposure, but investors should weigh macroeconomic factors affecting bond markets.
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vanguard Total International Bond Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the Bloomberg Global Aggregate ex-USD Float Adjusted RIC Capped Index (USD Hedged). This index provides a broad-based measure of the global, investment-grade, fixed-rate debt markets. It is non-diversified.
Read more on BNDX →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
